title: Chemo-radiotherapy and autologous bone marrow transplantation in poor prognosis neuroblastoma.
abstract: In Genoa, 39 patients affected by disseminated neuroblastoma, one to twelve years old, were treated with intensive chemotherapy (Vincristine 4 mg/sqm c.i. over 5 days, Melphalan 140 mg/sqm), total body irradiation (TBI) (3.3 Gy for 3 days), and unpurged autologous bone marrow transplantation (ABMT) since October 1984 until November 1987. Thirty-two patients were in complete response (first group) and 7 had residual disease (second group) after an intensive chemotherapeutic induction regimen. Actuarial overall survival at 38 months is 52% and disease free survival at 30 months is 28% for the first group. Actuarial overall survival at 25 months is instead 14% for the second group related treatment toxicity has not been too high (3 deaths).
authors: Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
authors: P
authors: P
authors: Franzone
authors: D
authors: D
authors: Scarpati
authors: V
authors: V
authors: Vitale
authors: R
authors: R
authors: Corvó
authors: S
authors: S
authors: Barra
authors: M
authors: M
authors: Guenzi
authors: M
authors: M
authors: Orsatti
authors: G
authors: G
authors: Dini
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009367:Neoplasm Staging; D009423:Nervous System Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D009447:Neuroblastoma / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D015996:Survival Rate; D014182:Transplantation, Autologous; D014916:Whole-Body Irradiation